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DIRECT AND INDIRECT COSTS OF ASTHMA TO 
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OBJECTIVES: Asthma is a debilitating condition that
can lead to significant adverse economic consequences.
This study investigated the extent that asthma imposes
significant financial burdens on the employer. METH-
ODS: The data source is an exceptionally rich adminis-
trative claims database for a national Fortune 100 manu-
facturer. It includes medical, pharmaceutical, and disability
claims for 1998 for employees, spouses, dependents, and
retirees (n  100,000). The research sample consisted of
individual patients with one or more medical or disability
claims for asthma. Resource utilization in the asthma
sample was contrasted with that of a 10% random sam-
ple of the employer’s overall beneficiary population. RE-
SULTS: The analysis included both direct (medical and
pharmaceutical) and indirect (disability and sporadic ab-
senteeism) costs. The average annual costs were: for the
entire employer population $2259; for asthma patients
$3962; for asthma patients eligible for disability $6983;
and for disability claimants with asthma $13,796. Total
costs for asthma patients were 1.8 times those for the
typical beneficiary. Medical and pharmaceutical treat-
ment accounted for 78% of total costs for asthma pa-
tients, while the remaining 22% was for wage replace-
ments for workdays lost for disability and sporadic
absenteeism. For employees, the average prevalence for
disability was 2.0 times greater among asthma patients
than among employees overall. CONCLUSIONS: Asthma
imposes a significant financial burden on the employer.
Resource utilization by asthma patients is substantial,
not only for the direct treatment of asthma, but also for
the treatment of co-morbid medical conditions of asthma
patients. The study also showed that asthma imposes
substantial indirect costs on employers, primarily from
the unusually high rates of disability associated with this
illness.
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Appropriate drug therapy, according to the guidelines by
the National Heart, Lung, and Blood Institute (NHLBI),
can improve patient’s quality of life and reduce total
treatment costs. However, few studies have assessed
changes in asthma treatment costs following adherence
to these guidelines. OBJECTIVES: The purpose of this
study was to evaluate the impact of a targeted asthma in-
tervention on treatment costs from the third party’s per-
spective. METHODS: This longitudinal population-based
study (1/1997–12/1998) compared asthma treatment
costs for 9 months before and 9 months after interven-
tion in intervention and control groups. A 3-month
washout period was applied to minimize any possible
carryover effects into the post-intervention phase. All
costs were deflated to 1997 dollars. Costs were also com-
pared based on patient’s drug therapy. A paired t-test or
a Wilcoxon signed rank test were used to compare costs
before and after the intervention, depending on the char-
acteristics of the sample. RESULTS: The intervention
group (IG) consisted of 1933 patients and the control
group (CG) consisted of 2447 patients. Following the in-
tervention, the average asthma medication cost per pa-
tient increased from $195 to $198 (P  0.357), but med-
ical costs decreased from $350 to $260 (P  0.05) in the
IG. The average number of asthma prescriptions per pa-
tient decreased from 6.69 to 6.30 in the IG (P  0.01)
while the number in the CG increased from 2.15 to 2.54
(P  0.01). The cost of asthma medications for patients
who use excess quick acting inhaled 2 agonist before in-
tervention but received proper drug therapy according to
the guidelines after intervention, increased from $91 to
$142 (P  0.01) however medical costs decreased from
$321 to $261 (P  0.05). CONCLUSIONS: A targeted
asthma intervention, according to the NHLBI guidelines,
resulted in a significant decrease in total asthma treat-
ment costs, with an increment in asthma medication
costs, but a decrease in asthma medical costs.
PRS3
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BACKGROUND: The excessive use of -agonist medica-
tions by asthmatics has been identified as a significant
risk factor for increased morbidity and mortality. The
objective of this analysis is to evaluate -agonist users in
BC to determine if -agonist utilization is decreasing, as
recommended by current asthma management guidelines.
METHODS: Asthma medication prescription records
were obtained from BC Pharmacare for all patients in BC
covered by Pharmacare who received at least one pre-
scription for a -agonist medication in 1996, 1997, and
1998. Annual -agonist use was standardized to salbutamol
100 mcg, 200 doses/canister. Cross-sectional and longitu-
dinal analyses were undertaken to identify potential
